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Inherited ichthyoses are a diverse group of genetic disorders characterized by dry,
scaly skin; hyperkeratosis; and altered skin-barrier function. While these disorders of
cutaneous keratinization are multifaceted and varying in etiology, disruption in the
stratum corneum with generalized scaling is common to all.1–4 Although not entirely
known how each diverse genetic process of the ichthyoses could lead to a similar
phenotype, a weakened epidermal barrier allowing for inflammation and subsequent
hyperproliferation of the skin is hypothesized.1–4
Various ichthyoses can be differentiated from one another through history, clinical
exam, histopathological analysis, electron microscopy, and genetics. Determining
the inheritance pattern is an important part of the family history; this information is
helpful in both formulating the differential diagnosis as well as in understanding the
variable expressivity and severity of the disorder.1,3,4 It is also important to know:
if the ichthyosis is congenital or was acquired later in adulthood; whether there is
a presence or absence of erythroderma; and the features and specific appearance of
the scale, as well as any other systemic manifestations of the disease.1,3,4 Although
histopathological analysis can be useful to differentiate some of the ichthyoses, such
as epidermolytic hyperkeratosis, other ichthyoses may not be able to be distinguished
from one another via this manner alone.1,3,4
Ichthyosis vulgaris (IV), the most frequently occurring ichthyosis, is caused by
mutations in the filaggrin gene (FLG).1,3–13 Typical hallmarks of IV, which encompass
a wide clinical spectrum, include visible scaling and dryness that spares flexural
surfaces, hyperlinearity of palms and soles, and strong predisposition for allergic
disease comorbidities.1,3–11 Prevalence estimates for IV range from 4.0% to 7.7% in
Europeans and 2.29% to 3.00% in Asians; observations of FLG mutations in darkly
pigmented populations are low.4,5,12,13
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Abstract: Here, we report a case of a middle-aged woman presenting with severe, long-standing,
hyperkeratotic plaques of the lower extremities unrelieved by over-the-counter medications.
Initial history and clinical findings were suggestive of an inherited ichthyosis. Ichthyoses are
genetic disorders characterized by dry scaly skin and altered skin-barrier function. A diagnosis
of ichthyosis vulgaris was confirmed by histopathology. Etiology, prevalence, and treatment
options are discussed.
Keywords: filaggrin gene, FLG, profilaggrin, keratohyalin granules, hyperkeratosis
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Case report
A 57-year-old female with new-onset dyspnea was evaluated
for severely hyperkeratotic skin of bilateral lower extremities
(Figures 1 and 2). The lesions were reported as beginning
during childhood, initially on the feet and progressing
proximally to the level of the knee. The lesions, which were
occasionally pruritic, had worsened over the prior 14 years
and were not relieved by over-the-counter medications.
Family history was significant for several generations of
males and females with similar appearing skin as well as
many unaffected family members. Our patient indicated
improvement in symptoms when living in warmer, more
humid environments with worsening of symptoms while
living at more northern latitudes.
Figure 2 Hyperkeratotic skin/hyperlinearity of the plantar surface.

Discussion

Figure 1 Hyperkeratotic skin of the lower extremity.
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IV, a genetically transmitted, autosomal semi-dominant
d isorder, exhibits varying penetrance of FLG mutations.4,6,8,13–19 Individuals heterozygous for the FLG mutation often have a less severe form of the disease than those
homozygous for the mutation.4,7,8,10,14–19 FLG encodes for a
protein called profilaggrin, which functions as a precursor
to filaggrin (or filament-aggregating protein).7 Profilaggrin
is stored in the granular layer of the epidermis as the major
component of keratohyalin granules.3,4,7,15 Profilaggrin is
cleaved into multiple filaggrin peptides that aggregate the
keratin filaments. These keratin filament complexes are then
cross-linked to the cell envelope and are important in maintaining the compact layer of skin and serving as a natural
moisturizer.3–5,6,8,16–19
It has long been established that IV is associated with
a decreased and even absent number of keratohyalin
granules due to the deficiency of filaggrin proteins.4,7,15
A compensatory epidermal hyperplasia with inflammation,
abnormal desquamation, and hyperkeratosis results in an
impaired epidermal barrier, water loss, and dehydration.1,9,16,20
Chemicals and allergens are more prone to cross the impaired
barrier, leading to sensitization and an increased propensity
for inflammatory skin conditions.1,4,21–23
IV is usually not clinically present at birth and may
have a variety of presentations later in life. With inherited
IV, symptoms usually begin before age 1 year and alternate between exacerbation and remission. With milder
presentations, patients present with flaky white scaling
patches, often on extremities and extensor surfaces, typically
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sparing the flexural and more hydrated areas of the body.3,4,15
More severe cases of IV are rare and may show an increased
hyperkeratosis of the palmoplantar skin with fissures
forming on the heels of the feet.1,4,15 The flaking scales may
be pronounced over the head, trunk, face, and extremities.
Intertriginous areas of the body (armpits, groin, etc), are
usually spared.1,4,15
Increased humidity explains the seasonal variation seen
in IV. Symptoms often improve in the summer months and
worsen in the cold and dry winter months, when the decreasing humidity further breaks down the residual filaggrin left
in the skin.1,4,15 IV is frequently associated with the atopic
triad of atopic dermatitis, hay fever, and asthma as well as
with keratosis pilaris.4–7,11,16,18,19 It is hypothesized that the
epidermal barrier abnormality continually exposes the body
to pathogens and allergens, ultimately resulting in a T-helper
2 immunophenotype consistent with atopy.4
Histopathologically, IV demonstrates orthohyperkeratosis, diminished to absent stratum granulosum, and decreased
or absent keratohyalin granules on electron microscopy.1,4 In
patients heterozygous for the gene mutation, the keratohyalin
granules may be present but appear small.3 Decreased or
absent filaggrin on immunohistochemistry is characteristic
as well.1,4
A histopathological analysis was done from a 4 mm
punch biopsy of the right lower leg of our patient. Findings
revealed orthohyperkeratosis with a markedly reduced
stratum granulosum, consistent with IV. Figure 3 shows the
histopathology of the punch biopsy specimen.
In this case, the severity of the IV was hypothesized to
be related to her obesity and chronic lymphedema. Obesity
is associated with mild chronic inflammation as well as
impaired lymphatic drainage due to tissue compression.24–27

Hyperkeratotic plaques of ichthyosis vulgaris

Lymphedema, the result of an inability of the lymphatic
vasculature to remove fluid and lipids, leads to their
accumulation in interstitial spaces.24–32 Recent reports also
note fibrotic changes in the extracellular matrix of adipose
tissue decrease lymphatic clearance of inflammatory
macromolecules from interstitial spaces.26,27
While lymphedema begins as spongy swelling, the chronic
recurring inflammation induces an infiltrate of fibroblasts and
keratinocytes thus transforming the epidermal layer leading
to its subsequent thickening.28–32 Over time, the limb with
untreated lymphedema gains a brawny and indurated texture
and histopathologically reveals hyperkeratosis and papillomatosis.28–32 Lymphedema-induced hyperkeratosis superimposed
on the epidermal thickening associated with IV likely played
a role in the exaggerated presentation in this case.
Treatment of IV is similar to that of many of the other
ichthyoses and is symptomatic, complex, and dynamic.9,20–23,33
Primary treatments are topical moisturizers and medications
designed to reduce scaling, support skin-barrier function,
reduce water loss, and decrease symptoms. Lessening the
scale, providing hydration, and moisturization can be accomplished with emollients, humectants, bathing immediately
followed with moisturizers, keratolytic agents, and topical
retinoids.20,21 Management of bacterial skin infections, most
commonly staphylococcal or streptococcal in origin, is done
with topical mupirocin or bacitracin.21,23 On the horizon,
researchers are attempting to use genetic pharmacology to
increase the body’s own production of normal filaggrin.4,15
For this patient, first-line treatment for IV was begun using
topical 0.1% tretinoin and 40% urea cream. At follow-up,
warm bath soaks prior to medication application was added
to the regimen to enhance absorption. At the present time,
marked objective clinical improvement, as well as subjective
patient satisfaction with treatment, is noted. She continues
to be followed in the dermatology clinic.

Conclusion
Our patient presented with an extreme presentation of a
common disease. Based upon the history, IV was considered.
However, the severity of the clinical presentation of hyperkeratosis strongly suggested an alternative diagnosis. This case
is a helpful reminder that IV is the most common inherited
ichthyosis, and therefore should be a diagnostic consideration
in even extreme and atypical presentations.
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